Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million |
| August 04, 2022 | August 2022 Bond Updates |
|
AACHEN, Germany, Aug. 4, 2022 /PRNewswire/ -- Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan... |
| View more at: https://www.prnewswire.com:443/news-releases/grunenthal-to-license-osteoarthritis-pain-treatment-to-shionogi-in-japan-in-deal-of-up-to---500-million-301599128.html |
| Related News |